Upgrade to SI Premium - Free Trial

ATARA Biotherapeutics (ATRA)

9.35 +0.19 (2.07%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/29/26)

Latest Headlines

FDA accepts resubmitted BLA for Atara's tabelecleucel with 2027 target date October 14, 2026 8:06 AM - StreetInsider Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration October 14, 2026 8:05 AM - BizWire Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration September 30, 2026 8:05 AM - BizWire Form 144 Atara Biotherapeutics, Filed by: Nguyen AnhCo August 26, 2026 7:48 PM - SEC Filing Form 4 Atara Biotherapeutics, For: Aug 17 Filed by: Nguyen AnhCo August 26, 2026 7:46 PM - SEC Filing TD Cowen Assumes Atara Biotherapeutics (ATRA) at Buy August 22, 2026 7:54 AM - StreetInsider Form SCHEDULE 13G/A Atara Biotherapeutics, Filed by: Point72 Asset Management, L.P. August 14, 2026 4:11 PM - SEC Filing Form 10-Q Atara Biotherapeutics, For: Jun 30 August 12, 2026 4:17 PM - SEC Filing ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 10c August 12, 2026 4:14 PM - StreetInsider Form 8-K Atara Biotherapeutics, For: Aug 12 August 12, 2026 4:11 PM - SEC Filing Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress August 12, 2026 4:05 PM - BizWire Form 4 Atara Biotherapeutics, For: Jul 22 Filed by: Redmile Group, LLC July 24, 2026 9:00 PM - SEC Filing Form SCHEDULE 13D/A Atara Biotherapeutics, Filed by: Redmile Group, LLC July 24, 2026 8:01 PM - SEC Filing Full Article List